ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
Treatments for pediatric craniopharyngiomas have traditionally included maximal safe surgical resection and radiation therapy to treat residual tumor. Additionally, intracystic therapies such as radioactive phosphorus P 32, bleomycin, and interferon-alpha have been used. Evidence has demonstrated that conservative surgical approaches lead to better neuroendocrine and quality-of-life outcomes in patients.[1,2] Additionally, as the biological understanding of molecular and inflammatory drivers of these tumors have been identified, targeted therapies are now being studied.
Table 1 describes the treatment options for newly diagnosed and recurrent childhood craniopharyngioma.
Sources: Table 1
| Treatment Group | Treatment Options |
|---|---|
| Newly diagnosed childhood craniopharyngioma | Complete resection with or without radiation therapy |
| Subtotal resection with radiation therapy | |
| Primary cyst drainage with or without radiation therapy | |
| Intracystic therapy | |
| Progressive or recurrent childhood craniopharyngioma | Surgery |
| Radiation therapy, including radiosurgery | |
| Intracystic therapy (intracavitary instillation of radioactive phosphorus P 32 or bleomycin for those with cystic recurrences, where these agents are available) | |
| Systemic and targeted therapy | |
| Observation |
Sources: Complete resection with or without radiation therapy · Subtotal resection with radiation therapy · Primary cyst drainage with or without radiation therapy · Intracystic therapy · Surgery · Radiation therapy, including radiosurgery · Intracystic therapy (intracavitary instillation of radioactive phosphorus P 32 or bleomycin for those with cystic recurrences, where these agents are available) · Systemic and targeted therapy · Observation
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
There is no consensus on the optimal treatment for patients with newly diagnosed craniopharyngioma, in part because of the lack of prospective randomized trials that compare the different treatment options. Treatment is individualized on the basis of the following factors:
Tumor size.
Tumor location.
Extension of the tumor.
Potential short-term and long-term toxicity, partially related to baseline neuroendocrine and vision deficits (i.e., more conservative surgical approaches may be prioritized in patients who do not have existing neuroendocrine or visual deficits to mitigate the risk of surgical morbidity).[1]
Sources: 1
Established treatment options for newly diagnosed childhood craniopharyngioma include the following:
Complete resection with or without radiation therapy.
Sources: Complete resection with or without radiation therapy
Subtotal resection with radiation therapy.
Primary cyst drainage with or without radiation therapy.
Sources: Primary cyst drainage with or without radiation therapy
Intracystic therapy.
Sources: Intracystic therapy
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
It may be possible to remove all visible tumor and achieve long-term disease control.[2-4][Level of evidence C1] A 5-year progression-free survival (PFS) rate of about 65% has been reported.[5] Reported recurrence rates range from less than 10% to nearly 50%.[6,7] Gross-total resection is often technically challenging because the tumor is surrounded by vital structures, including the optic nerves and chiasm, the carotid artery and its branches, the pituitary and hypothalamus, and the third cranial nerve. These structures may limit the ability to remove the entire tumor. Conservative surgical approaches are often used to preserve functional and quality-of-life outcomes.[8,9][Level of evidence C1]
Sources: 2 · 4 · Level of evidence C1 · 5 · 6 · 7 · 8 · 9 · Level of evidence C1
Many surgical approaches have been described, and the choice is determined by tumor size, location, extension, and the patient's baseline signs and symptoms of disease. Surgical approaches include the following:
Craniotomy: As noted above, gross-total resection may be technically challenging because the tumor is surrounded by vital structures. The surgeon often has a limited view of the hypothalamic and sellar regions, and portions of the mass may remain after surgery, accounting for some recurrences. An understanding of the complex variations in how the tumors grow anatomically may help facilitate gross-total resection.[10] Nonetheless, almost all craniopharyngiomas attach to the pituitary stalk. Of the patients who undergo complete resection, virtually all will require lifelong pituitary hormone replacement with multiple medications.[3,11]
Transsphenoidal approach: A transsphenoidal approach has been proven possible in patients of all ages and for tumors of various sizes localized within the sella.[12]; [13][Level of evidence C1] The development of expanded endonasal techniques with endoscopic visualization has allowed increased use of this approach, even for sizeable childhood tumors, which is similar to the experience in adults.[14] A complete resection can be obtained using this approach, with associated complications of panhypopituitarism and the risk of cerebrospinal fluid leaks.[15,16] When an endonasal approach is not possible, a craniotomy is required.
Complications of complete resection using either approach include the following:
Obesity, which can be life-threatening.[17]
Sources: 17
Need for hormone replacement therapy.[18]
Sources: 18
Severe behavioral problems.[18]
Sources: 18
Blindness.
Seizures.
Spinal fluid leak.
False aneurysms.
Difficulty with eye movements.
Death from intraoperative hemorrhage, hypothalamic damage, or stroke (rare).
If the surgeon indicates that the tumor was not completely removed or if postoperative imaging reveals residual craniopharyngioma, radiation therapy may be recommended to prevent early progression.[19][Level of evidence C2] For more information, see the Subtotal Resection With Radiation Therapy section.
Sources: 19 · Level of evidence C2 · Subtotal Resection With Radiation Therapy
Routine surveillance using magnetic resonance imaging is performed for several years after complete resection because of the possibility of tumor recurrence.
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
The goal of limited surgery can be to establish a diagnosis, drain cystic components of the tumor, and decompress surrounding anatomical structures. In subtotal resections, removal of the tumor from the pituitary stalk or hypothalamus is typically avoided to minimize the late effects associated with complete resection.[20]
Sources: 20
Surgery is often followed by radiation therapy, because radiation therapy can decrease the risk of recurrence after a subtotal resection.[21] With this approach, the 5-year PFS rates are approximately 70% to 90%,[5,22-25]; [26][Level of evidence C1] and the 10-year overall survival (OS) rates exceed 90%, which are similar to the rates in patients who undergo a gross-total resection.[27,28][Level of evidence C1]; [29][Level of evidence C2] Most often, radiation therapy is timed to immediately follow subtotal resection. However, in certain cases, such as in young patients or in patients without existing neuroendocrine or visual deficits, serial imaging may be used to delay or avoid radiation therapy for as long as feasible.[7,30] The standard approach to radiation therapy involves fractionated external-beam radiation, with a recommended dose of 50 to 54 Gy, in 1.8-Gy fractions, restricting the optic chiasm dose to 54 Gy.[31-34] Newer radiation technologies such as intensity-modulated photon therapy and proton-beam radiation therapy may reduce the radiation dose to uninvolved parts of the brain and spare normal tissue.[23,34-36] It is unknown whether such techniques reduce the late effects of radiation therapy.[26,34,36,37] Transient cyst enlargement may be noted during radiation therapy, and serial imaging may be required during radiation therapy to assess cyst changes and consider updates to radiation mapping.[38][Level of evidence C3]
Sources: 21 · 5 · 22 · 25 · 26 · Level of evidence C1 · 27 · 28 · Level of evidence C1 · 29 · Level of evidence C2 · 7 · 30 · 31 · 34 · intensity-modulated photon therapy · proton-beam radiation therapy · 23 · 34 · 36 · 26 · 34 · 36 · 37 · 38 · Level of evidence C3
Surgical complications with a subtotal resection can be similar to, but are less likely than, with a complete resection. If radiation therapy is used, additional complications must be considered, including the following:
Loss of pituitary hormonal function.
Cognitive dysfunction.
Development of late strokes and vascular malformations.
Delayed blindness.
Development of second tumors.
Malignant transformation of the primary tumor within the radiation field (rare).[39,40]
A phase II single-arm study included 94 patients (aged 12 months to 21 years) with craniopharyngiomas who were treated with proton-beam radiation therapy after individualized surgical resection. These patients were compared with a historical cohort of patients who were treated with photon-beam radiation therapy.[41] The survival outcomes of patients who received proton therapy were similar to those of patients who received photon therapy. The cumulative incidence rates of necrosis, vasculopathy, changes in vision, and severe complications were also similar between the two groups of patients. However, patients treated with proton therapy in the more recent cohort had superior cognitive outcomes.
Sources: proton-beam radiation therapy · 41
A long-term study of 101 children who were treated for craniopharyngiomas evaluated visual, neurocognitive, and endocrine outcomes after photon radiation therapy. Race and presence of a shunt affected baseline scores.[42] For children who presented with lower intelligence quotient (IQ) scores at diagnosis, the impact of treatment often resulted in an IQ score reduction to the borderline mental disability range of 70 to 84. The investigators demonstrated that age at treatment (younger children had worse outcomes), radiation dose to the temporal lobes and hippocampi, and visual impairment significantly impacted neurocognitive function after radiation therapy. This study demonstrates the importance of these factors in the treatment and late effects of craniopharyngioma.
Sources: 42
A report from the prospective registry study KiProReg examined the use of proton-beam therapy in 84 children younger than 18 years with craniopharyngioma.[43] The estimated 3-year OS rate was 98.2%, and the PFS rate was 94.7%. With a median follow-up of 4.3 years, late toxicities appeared acceptable. Sixty-three of the patients were treated with pencil-beam scanning, which is considered an advancement in proton technology.
Sources: 43
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
For predominantly cystic craniopharyngiomas, stereotactic drainage of the cyst, insertion of a catheter from which drainage can be facilitated, or cyst fenestration are other therapeutic alternatives.[7,44] This can be followed by observation or radiation therapy, depending on clinical and tumor characteristics . This procedure may also allow the surgeon to use the following two-staged approach:[45]
Draining the cyst to relieve pressure and complicating symptoms.
Resecting the tumor or employing radiation therapy later.
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
Intracystic therapies include peginterferon alpha, radioactive phosphorus P 32 (32P) or other compounds,[46-48]; [49][Level of evidence B4] and interferon-alpha (which is no longer commercially available).[50]; [51][Level of evidence C1]; [52][Level of evidence C2] Bleomycin has previously been used.[53]; [54][Level of evidence C2]
Sources: 46 · 48 · 49 · Level of evidence B4 · 50 · 51 · Level of evidence C1 · 52 · Level of evidence C2 · 53 · 54 · Level of evidence C2
A systematic review of publications on the treatment of cystic craniopharyngiomas with radioisotope brachytherapy from 2010 to 2021 identified 66 pediatric patients (N = 228).[55] With a minimum follow-up of 5 years, partial and complete responses were achieved in 89% of children with purely cystic lesions, compared with 58% of children with nonexclusively cystic lesions. Visual improvement was achieved in 64% of the patients with purely cystic lesions, and endocrine improvement was achieved in 20% of these patients. The observed progression rate was 3% for patients with purely cystic lesions. Treatment with intracystic brachytherapy, most commonly using 32P and yttrium Y 90, can be considered for patients with purely cystic craniopharyngiomas.
Sources: 55
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Preclinical contemporary evaluations have identified active molecular and immune pathways in craniopharyngioma that may be targetable using commercially available or investigational agents. Specifically, MAPK and RAF pathways and immune/inflammatory targets such as PD-1 pathway components and IL-6 have been identified.[7,56-61][Level of evidence C1]
Sources: 7 · 56 · 61 · Level of evidence C1
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT05465174 (Nivolumab and Tovorafenib [DAY101] for Treatment of Craniopharyngioma in Children and Young Adults): This study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF kinase (tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Sources: NCT05465174
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
Progression or recurrence of craniopharyngioma varies according to the type of up-front therapy, but it has been reported to be between 20% (patients who received a subtotal resection and radiation therapy) and 90% (patients who received a subtotal resection without radiation therapy).[1-3]
Treatment options for recurrent childhood craniopharyngioma include the following:
Surgery.
Sources: Surgery
Radiation therapy, including radiosurgery.
Intracystic therapy (intracavitary instillation of radioactive phosphorus P 32 [32P] or bleomycin for those with cystic recurrences, where these agents are available).
Systemic targeted therapy.
Sources: Systemic targeted therapy
Observation.
Sources: Observation
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
The management of recurrent craniopharyngioma is determined largely by previous therapy. Repeat attempts at gross-total resections are difficult, and long-term disease control is achieved less often.[4][Level of evidence C2]; [3] Complications are more frequent than with initial surgery.[5][Level of evidence C2]
Sources: 4 · Level of evidence C2 · 3 · 5 · Level of evidence C2
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
If not previously employed, external-beam radiation therapy remains an option, including the consideration of radiosurgery in selected circumstances.[6][Level of evidence C2] Repeat irradiation in different forms is also an option when considering prior radiation exposures and toxicities. Reirradiation has been shown to be feasible in regaining tumor control and providing symptom relief.[7][Level of evidence C3] The types of radiation therapy can range from standard conformal radiation approaches to Gamma Knife therapy.[8][Level of evidence C3]
Sources: radiosurgery · 6 · Level of evidence C2 · 7 · Level of evidence C3 · 8 · Level of evidence C3
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
Cystic recurrences may be treated with intracavitary instillation of varying agents via placement of an Ommaya catheter.[9] These agents have included radioactive 32P or other compounds,[10-12]; [13][Level of evidence B4] bleomycin,[14]; [15][Level of evidence C2] or, previously, interferon-alpha (which is no longer commercially available).[16]; [17][Level of evidence C1]; [18][Level of evidence C2] These strategies have been useful in certain cases, and a low risk of complications has been reported. However, none of these approaches has shown efficacy against solid portions of the tumor.
Sources: 9 · 10 · 12 · 13 · Level of evidence B4 · 14 · 15 · Level of evidence C2 · 16 · 17 · Level of evidence C1 · 18 · Level of evidence C2
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
Although systemic therapy is generally not used, a small series has shown that the use of subcutaneous peginterferon alpha-2b to manage cystic recurrences can result in durable responses; however, this agent is no longer commercially available.[19][Level of evidence C2]
Sources: 19 · Level of evidence C2
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
In select cases of asymptomatic patients with minimal (<25%) tumor progression, it may be possible to safely observe these patients. Intervention can begin when new symptoms develop or further tumor growth is identified on subsequent imaging.[20]
Sources: 20
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Preclinical contemporary evaluations have identified active molecular and immune pathways in craniopharyngioma that may be targetable using commercially available or investigational agents. Specifically, MAPK and RAF pathways and immune/inflammatory targets such as PD-1 pathway components and IL-6 have been identified.[21-27][Level of evidence C1]
Sources: 21 · 27 · Level of evidence C1
The following are examples of national and/or institutional clinical trials that are currently being conducted:
NCT05465174 (Nivolumab and Tovorafenib [DAY101] for Treatment of Craniopharyngioma in Children and Young Adults): This study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF kinase (tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Sources: NCT05465174
NCT05286788 (Binimetinib [Mektovi] for the Treatment of Pediatric Adamantinomatous Craniopharyngioma): This phase II study will treat pediatric patients diagnosed with recurrent adamantinomatous craniopharyngioma with binimetinib (mektovi).
Sources: NCT05286788
NCT05233397 (Tocilizumab [Actemra] for the Treatment of Progressive or Recurrent Pediatric Adamantinomatous Craniopharyngioma): This phase II study will treat pediatric patients diagnosed with recurrent adamantinomatous craniopharyngioma with tocilizumab (actemra).
Sources: NCT05233397
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024. Captured 2026-09-09.
Quality-of-life issues are important to pediatric patients with craniopharyngiomas and are difficult to generalize because of the various treatment modalities. In one series of 261 patients diagnosed with craniopharyngiomas before 2000, hypothalamic involvement was associated with lower overall survival (OS), impaired quality of life, and severe obesity.[1][Level of evidence C1] Other studies investigating quality of life in large, multi-institutional cohorts have correlated worse quality-of-life outcomes with variables such as older age at diagnosis, hypothalamic involvement, degree of postoperative hypothalamic injury, and degree of tumor resection.[2,3] Regardless of therapy, most patients with craniopharyngiomas experience long-term effects from the tumor and associated therapies.[2-6][Level of evidence B3]
Sources: 1 · Level of evidence C1 · 2 · 3 · 2 · 6 · Level of evidence B3
Late effects of treatment for childhood craniopharyngioma include the following:
Behavioral issues and memory deficits. Although intelligence quotient is usually maintained, behavioral issues and other cognitive domains such as memory, executive function, and attention are commonly impacted.[4,6-8] Memory and neurocognitive effects may be mitigated by the use of proton radiation therapy and conformal plans to avoid surrounding normal brain anatomy such as the hypothalamus and hippocampus.[9]; [10][Level of evidence B3]
Visual disturbances. Visual disturbances, including visual field and acuity defects, have been reported. These deficits may be decreased with less aggressive surgical approaches or radiation therapy alone.[11][Level of evidence C1]; [6,10]
Sources: 11 · Level of evidence C1 · 6 · 10
Endocrine abnormalities. Endocrine abnormalities result in the almost universal need for lifelong endocrine replacement with multiple pituitary hormones.[5,8]; [12-14][Level of evidence C1] Similar to visual disturbances, endocrine injury can be offset by limited surgical resection [5,6,15-17] and intracystic therapies that minimize invasive interventions.[18]
Sources: 5 · 8 · 12 · 14 · Level of evidence C1 · 5 · 6 · 15 · 17 · 18
Decreased height. Growth hormone replacement therapy is used to improve growth in children treated for craniopharyngiomas. Growth hormone replacement initiated in childhood results in increases in height without impact on OS and progression-free survival when compared with children who did not receive growth hormone.[19][Level of evidence C1]; [20] Growth hormone administration beginning 1 year after diagnosis may be associated with early improvements in quality of life when measured at 3 years postdiagnosis.[21][Level of evidence C1] Published consensus guidelines do not support an increased risk of recurrence with use of growth hormones. They recommend considering growth hormone replacement therapy as early as 3 months after completing cancer therapy in patients who have stable disease and significant growth deficits.[22][Level of evidence D]
Sources: 19 · Level of evidence C1 · 20 · 21 · Level of evidence C1 · 22 · Level of evidence D
Obesity. Obesity, which can be life-threatening, and the development of metabolic syndrome, including nonalcoholic fatty liver disease, can occur.[23,24] Children who undergo complete resection or subtotal resection may develop obesity, suggesting that a predilection to obesity may be a component of the disease itself, not the result of direct hypothalamic injury.[25][Level of evidence C1] Severe obesity seen in patients with craniopharyngiomas is more likely a result of a combination of factors such as tumor location and treatment characteristics, with multifaceted downstream impacts.[26][Level of evidence C1] In a study of 709 patients with craniopharyngiomas, posterior hypothalamic involvement or operative injury to the posterior hypothalamus appeared to be a key factor in the development of severe obesity.[3]
Sources: 23 · 24 · 25 · Level of evidence C1 · 26 · Level of evidence C1 · 3
Vasculopathies and stroke. Vasculopathies and subsequent strokes may result from local irradiation.[27,28] Previous studies have suggested that long-term growth hormone replacement may reduce the risk of stroke. Studies have also shown that pretreatment characteristics such as existing vascular injury, vessel location in the surgical field, and larger radiation doses to vascular structures increase the risk of long-term vessel stenosis.[28]; [29][Level of evidence C1] In a study of 94 pediatric patients with craniopharyngiomas who were treated with surgery and 54 Gy of proton therapy, the strongest predictor of postradiation therapy vasculopathy was preexisting vasculopathy.[29] The impact of proton radiation therapy was negligible within the operative corridor. Despite the high incidence (n = 27, 28.7%) of imaging-only evidence of subclinical stenosis events, only five patients required a revascularization procedure. In one of these patients, high-grade stenosis was present before radiation therapy. Two patients had previous tumor recurrences that required multiple resections before radiation therapy.
Subsequent neoplasms. Subsequent neoplasms may result from local irradiation.[27] Secondary malignancies related to radiation therapy that specifically involve the pituitary/sellar region can range from malignant tumors, such as high-grade gliomas, to meningiomas. This risk is increased in patients who are younger at the time of radiation therapy.[30]
For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment for childhood craniopharyngioma. The pediatric oncologist works with other health care providers who are experts in treating children with brain tumors and who specialize in certain areas of medicine. Other specialists may include:
pediatrician
Sources: pediatrician
neurosurgeon
Sources: neurosurgeon
radiation oncologist
Sources: radiation oncologist
neurologist
Sources: neurologist
endocrinologist
Sources: endocrinologist
ophthalmologist
Sources: ophthalmologist
rehabilitation specialist
Sources: rehabilitation specialist
psychologist
Sources: psychologist
social worker
Sources: social worker
nurse specialist
Sources: nurse
There are different types of treatment for children and adolescents with craniopharyngioma. Although craniopharyngioma is not cancer, treatment is often similar to cancer treatment and may include surgery, radiation therapy, and other approaches. You and your child's care team will work together to decide treatment. Many factors will be considered, such as your child's age and overall health, where the tumor is located and whether it has spread into nearby tissue, and the possible side effects and late effects of treatment.
Your child's treatment plan will include information about the tumor, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.
Types of treatment your child might have include:
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
The type of surgery your child will have depends on the size of the tumor, where it is in the brain, and whether it has grown into nearby tissue in a finger-like way. It also depends on expected late effects that may occur after surgery.
The types of surgery that may be used to remove the tumor that can be seen with the eye include:
Transsphenoidal surgery is a type of surgery in which a surgeon inserts instruments into the brain by going through a cut made under the upper lip or at the bottom of the nose between the nostrils. Then they go through the sphenoid bone (a butterfly-shaped bone at the base of the skull) to reach the tumor near the pituitary gland and hypothalamus.
A craniotomy is surgery to remove the tumor through an opening made in the skull.
To help make a diagnosis, sometimes the surgeon will remove only part of the tumor. If a tumor is near the pituitary gland or hypothalamus, it will not be removed. Leaving the tumor helps reduce serious side effects from the surgery.
Sometimes, the surgeon will remove all of the tumor that they can see and no further treatment is needed. At other times, they may not be able to remove the tumor because it is growing into or pressing on nearby organs.
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
If your child's tumor is mostly a fluid-filled cyst, they may have surgery to drain it. Draining it lowers the pressure in the brain and relieves symptoms.
A surgery called a partial resection can be used to remove fluid from cystic craniopharyngiomas. Or a thin tube called a catheter can be inserted into the cyst, and a small container placed under the skin. The fluid drains into the container and is later removed.
Sometimes, after the cyst is drained, a drug is put through the catheter into the cyst. This causes the inside wall of the cyst to scar and stops the cyst from making fluid. Or it can slow down how long it takes for the fluid to build up again. Surgery to remove the tumor or radiation therapy may be done after the cyst is drained.
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill tumor cells or keep them from growing. It is often given after surgery to kill any tumor that is left in the brain.
Both external radiation therapy and internal radiation therapy (also called brachytherapy) are used to treat craniopharyngiomas.
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with the tumor.
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the tumor.
Sources: radioactive · seeds
Radiation therapy to the brain can affect growth and development in young children, so ways of giving radiation therapy that have fewer side effects are often used. These include:
Stereotactic radiosurgery may be used for very small craniopharyngiomas at the base of the brain. For this treatment, a rigid head frame is attached to the skull to keep the head still during the treatment. Then, a machine aims a single large dose of radiation directly at the tumor. This procedure is a type of radiation therapy and does not involve surgery. It is also called stereotaxic radiosurgery, radiosurgery, and radiation surgery.
Intracavitary radiation therapy is a type of internal radiation therapy that may be used in tumors that are part solid mass and part fluid-filled cyst. For this treatment, radioactive material is placed inside the tumor. This type of radiation therapy causes less damage to the nearby hypothalamus and optic nerves.
Intensity-modulated photon therapy is a type of radiation therapy that uses x-rays or gamma rays that come from a special machine called a linear accelerator (linac) to kill tumor cells. A computer is used to target the exact shape and location of the tumor. Then thin beams of photons of different strengths are aimed at the tumor from many angles. This type of 3-dimensional radiation therapy may cause less damage to healthy tissue in the brain and other parts of the body.
Sources: photon · gamma rays · linear accelerator · 3-dimensional radiation therapy
Proton-beam radiation therapy is a type of radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. This treatment can reduce the amount of radiation damage to healthy tissue near a tumor.
Learn more about Radiation Therapy to Treat Cancer.
Sources: Radiation Therapy to Treat Cancer
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of tumor cells. Chemotherapy either kills the tumor cells or stops them from dividing.
Chemotherapy can be placed directly into a cavity, such as a cyst. This way of giving chemotherapy is intracavitary chemotherapy. Bleomycin is a type of chemotherapy that can be placed directly into a cystic craniopharyngioma.
Sources: cavity · intracavitary · Bleomycin
Learn more about Chemotherapy to Treat Cancer.
Sources: Chemotherapy to Treat Cancer
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Observation means that your child's condition is closely watched without receiving treatment until symptoms appear or change.
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Treatment of newly diagnosed childhood craniopharyngioma may include:
complete removal of the tumor with surgery with or without radiation therapy
partial removal of the tumor with surgery followed by radiation therapy
cyst drainage, followed by observation, radiation therapy, or surgery
brachytherapy or chemotherapy placed directly in the cyst or tumor
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Treatment options for progressive or recurrent childhood craniopharyngioma depend on the type of treatment that your child received when the tumor was first diagnosed and your child's needs.
Sources: progressive · recurrent
Treatment may include:
surgery
external-beam radiation therapy
brachytherapy or intracavitary chemotherapy
observation
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Childhood Craniopharyngioma (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Cancer treatments used for craniopharyngioma can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Problems from treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of treatment may include:
seizures
Sources: seizures
bone and muscle growth and development
behavior problems
changes in mood, feelings, thinking, learning, or memory
second cancers (new types of cancer)
Serious physical problems may occur if the pituitary gland, hypothalamus, optic nerves, or carotid artery are affected during surgery or radiation therapy. These problems include:
Sources: carotid artery
obesity
Sources: obesity
metabolic syndrome, including fatty liver disease not caused by drinking alcohol
Sources: metabolic syndrome
vision problems, including blindness
blood vessel problems or stroke
Sources: blood vessel · stroke
loss of the ability to make certain hormones
Some late effects may be treated or controlled. Your child may need life-long hormone replacement therapy with several medicines. It is important to talk with your child's doctors about the effects treatment can have on your child. Learn more about Late Effects of Treatment for Childhood Cancer.
Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
ClinicalTrials.gov recordAdamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
ClinicalTrials.gov recordCraniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
ClinicalTrials.gov recordChildhood Craniopharyngioma
ClinicalTrials.gov recordTreatment of Newly Diagnosed Childhood Craniopharyngioma
Craniopharyngioma in children and adolescents
Treatment of Progressive or Recurrent Childhood Craniopharyngioma